

Prezentační aktivity Kliniky hematologie v zahraničí - výběr

1 – 12/ 2018

3/2018 Rumunsko

- **Hájek R.** The role of minimal residual disease in MM in 2018. **Hematology Chronic Dialogues**, Cluj-Napoca, Romania, 3/2018
- **Hájek R.** Practical management of daratumumab in patients with MM in Czech Republic. **Hematology Chronic Dialogues**, Cluj-Napoca, Romania, 3/2018

2/2018 Polsko

- **Hájek R.** Immunomodulation & Immunotherapy in MM. **8. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2018

1 – 12/ 2017

11/2017 Rakousko

- **Hájek R.** Guideline overview, recent changes, and implications for Central Eastern Europe. **Multiple Myeloma Expert Forum Meeting**, Vienna, Austria, 11/2017

10/2017 Polsko

- **Hájek R.** Treatment of plasma cell myeloma. State of the art. **Conference on Progress in oncology**, Gliwice, Poland, 10/2017
- **Hájek R.** Chairman of the Bone marrow transplantology session. **Conference on Progress in oncology**, Gliwice, Poland, 10/2017

9/2017 Česká republika

- **Hájek R.** Relapsed and/or Refractory Multiple Myeloma treatment landscape across North East Europe. **MM Expert Panel Meeting**, Prague, Czech Republic, 9/2017
- **Hájek R.** MGUS & Smoldering Myeloma. How to predict outcome & “To treat or not to treat”. **IMS Educational Workshop**, Prague, Czech Republic, 9/2017
- **Hájek R.** Co-Chair of the workshop. **IMS Educational Workshop**, Prague, Czech Republic, 9/2017

9/2017 Polsko

- **Hájek R.** Novel diagnostic methods in multiple myeloma. When should we start the treatment? **27th Congress of the Polish Society of Hematology and Transfusion Medicine**, Warsaw, Poland, 9/2017

7/2017 Švýcarsko

- **Hájek R.** 3. Response in an elderly, comorbid RRMM patient ineligible for ASCT, **Multiple Myeloma (MM) European Advisory Board**, Zurich, Switzerland, 7/2017

6/2017 Španělsko

- **Hájek R.** Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). **22st Congress of the European Hematology Association (EHA)**, Madrid, Spain, 6/2017

5/2017 Německo

- **Hájek R.** Single vs. double transplantation. **6th Heidelberg Myeloma Workshop**, Heidelberg, Germany, 5/2017

4/2017 Polsko

- **Hájek R.** Multiple myeloma therapy – beyond 2017. **Conference „Hematology – how to treat ...in 2017”**, Wroclaw, Poland, 4/2017

4/2017 Slovensko

- **Hájek R.** Current and future treatment options for Multiple Myeloma, focus to relaps/ refractory. **Ninlaro Deep Dive Medical Training**, Bratislava, Slovak Republic, 4/2017

3/2017 Indie

- **Hájek R.** Oral session chair - Session 2: Novel Drug Targets. **16th International Myeloma Workshop**, New Delhi, India, 3/2017

2/2017 Polsko

- **Hájek R.** Transplant Not-eligible Patients. **7. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2017

1 – 12/ 201610/2016 Slovensko

- **Hájek R.** Léčebný pokrok u relabujícího mnohočetného myelomu. **VIII. Bratislavské hematologické a transfuziologické dni**. Bratislava, Slovak Republic, 10/2016

9/2016 Finsko

- **Hájek R.** Triplet Therapies for Relapsed Multiple Myeloma and the Role of Cytogenetic Testing and Risk Assessment in Treatment Selection. **Annual intensive day meeting for Finnish haematologists, 'Intensive day warm-up'**, Helsinki, Finland, 9/2016,

7/2016 Rakousko

- **Hájek R.** Pro & Contra-Session: „Good bye to CRAB - should we treat MM earlier ?“ and how**FIRST AUSTRIAN MYELOMA SUMMER SCHOOL 2016**. Salzburg, Austria, 7/2016

6/2016 Jihoafrická republika

- **Hájek R.** Toward the Cure - Multiple Myeloma. **4th African Pharma Congress**. Cape Town, South Africa, 6/2016

6/2016 Dánsko

- **Hájek R.** - chair of the Education Session on “Multiple myeloma. 21st Congress of the European Hematology Association (**EHA**). Copenhagen, Denmark, 6/2016.

5/2016 Polsko

- **Hájek R.** Do we still need alkylators in the era of IMiD's and PI's? **II Międzynarodowa Konferencja Szkoleniowa “Hematologia Kliniczna i Doświadczalna”**, Kazimierz Dolny, Poland, 5/2016

5/2016 Slovensko

- **Gumulec J.** Heparinem indukovaná trombocytopenie. **XXIII.Slovensko-česká konferencia o hemostáze a trombóze**. Martin, Slovak Republic. 5/2016
- **Hájek R.** Současný význam Minimal Residual Disease u mnohočetného myelomu. **Myelomové fórum 2016**, Bratislava, Slovak Republic, 5/2016
- **Kaščák M.** Raritní diagnózy v hematologii. Amyloidóza a Waldenströmova makroglobulinémie, **Myelomové fórum 2016**, Bratislava, Slovak Republic 5/016

4/2016 Slovinsko

- **Hájek R.** The new therapies and challenges in treating Multiple Myeloma. **5th CONGRESS OF SLOVENIAN HAEMATOLOGICAL SOCIETY**. Laško, Slovenia. 4/2016

2/2016 Polsko

- **Hájek R.** Pathophysiology of MM and targets for existing & future drugs and their Combinations. **6. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, 2/2016

1/2016 Polsko

- **Hájek R.** Sequential treatment and modern therapies for Multiple Myeloma. **Haematologic Workshop**, Szczecin, Poland 1/2016

1 – 12/ 2015

12/2015 USA

- Wee-Joo Chng, H. Goldschmidt, M.A. Dimopoulos, P. Moreau, D. Joshua, A. Palumbo, T. Facon, H. Ludwig, L. Pour, R. Niesvizky, A. Oriol, L. Rosiñol, A. Suvorov, G. Gaidano, T. Pika, K. Weisel, V. Goranova-Marinova, H. Gillenwater, N. Mohamed, S. Feng, **R. Hájek**. Efficacy and Safety of Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis From the Phase 3 Study ENDEAVOR (NCT01568866). **American Society of Hematology - 57th Annual Meeting**, Orlando, USA, December 2015.
- P. Moreau, D. Joshua, Wee-Joo Chng, A. Palumbo, H. Goldschmidt, **R. Hájek**, et al. Impact of Prior Treatment on Patients With Relapsed Multiple Myeloma Treated With Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 ENDEAVOR Study (NCT01568866). **American Society of Hematology - 57th Annual Meeting**, Orlando, USA, December 2015.

9/2015 Itálie

- **Hájek R.** Ongoing Studies/Open Questions in Europe. **15th International Myeloma Workshop**. Roma, Italy, September 2015.

9/2015 Slovenská republika

- **Hájek R.** Kam kráčíš, myelome? Léčebné strategie současnosti. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- **Kaščák M., Hájek R.** Novinky v diagnostice a léčbě Waldenströmovy makroglobulinémie, **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.
- **Tóthová E.** Výskyt a manažment nežiaducich účinkov inhibítorov tyrozínkinázy počas liečby chronickej myelocytovej leukémie. **XVII. Slovensko český hematologický a transfuziologický zjazd**. Bratislava, The Slovak Republic, September 2015.

- Jelínek T, **Hájek R.** Nové perspektivní léky v léčbě mnohočetného myelomu. **XVII. Slovensko český hematologický a transfuziologický zjazd.** Bratislava, The Slovak Republic, September 2015.
- Vladimír Maisnar, Jana Pelcová, Jiří Jarkovský, **Roman Hájek.** AKTUÁLNÍ VÝSTUPY Z REGISTRU MONOKLONÁLNÍCH GAMAPATIÍ CMG. **XVII. Slovensko český hematologický a transfuziologický zjazd.** Bratislava, The Slovak Republic, September 2015.

6/2015 Rakousko

- **Hájek R.** - předsednictví sekce Multiple myeloma: Clinical studies 2. **EHA 2015**, Vienna, Austria, June 2015.
- M.A. Dimopoulos, P. Moreau, A. Palumbo, D. Joshua, L. Pour, **R. Hájek** et al. Carfilzomib and Dexamethasone Improves Progression-Free Survival and Response Rates vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: the Phase 3 Study ENDEAVOR. **EHA 2015**, Vienna, Austria, June 2015.
- Meletios A. Dimopoulos, A. Keith Stewart, S. Vincent Rajkumar, Tamás Masszi, Ivan Špička, Albert Oriol, **Roman Hájek.** Effect of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma by Line of Therapy: Interim Results From the Phase 3 Study ASPIRE Study. **EHA 2015**, Vienna, Austria, June 2015.

5/2015 Polsko

- **Hájek R.** The Czech Myeloma Group. **10th Anniversary of the Polish Myeloma Group "Multiple Myeloma: present facts and future expectations"**, Lublin, Poland, May 2015.

5/2015 Slovensko

- **Hájek R.** Čo možno očakávať od pomalidomidu. **Myelómové Fórum 2015.** Piešťany, The Slovak Republic, May 2015.

4/2015 Německo

- **Hájek R.** Long term continuous therapy. **5th Heidelberg Myeloma Workshop: Current status and developments in diagnosis and therapy of Multiple Myeloma.** Heidelberg, Germany, April 2015.

4/2015 Velká Británie

- **Hájek R.** - předsednictví sekce Monitoring Multiple Myeloma. **7th International Symposium: Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis**, Edinburgh, Great Britain, April 2015.

1/2015 Polsko

- **Hájek R.** Progress in unravelling the molecular biology of multiple myeloma. **5. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2015.

1 – 12/ 2014

12/2014 Švýcarsko

- Hájek R. Aspire data presentation. **Kyprolis after ASH Meeting.** Zurrich, Switzerland, December 2014.

11/2014 Řecko

- **Hájek R.** MYELOMA STEM CELLS. **2nd International Conference on Multiple Myeloma**, Athens, Greece, November 2014.

8/2014 Velké Británie

- **Hájek R.** Waldenström macroglobulinemia in Czech Republic. **ECWM Meeting at 8th International Workshop on WM**, London, England, August 2014.

4/2014 Itálie

- **Hájek R.** - předsednictví sekce Plenary 8: Myeloma Cooperative Trials in Progress. **European Society for Blood and Marrow Transplantation Meeting**, Milan, Italy, April 2014.

4/2014 Německo

- **Hajek R.** Scientific progress, results and exploitation. **OPTATIO - Partner meeting 2014**, Würzburg, Germany, April 2014.

2/2014 Polsko

- **Hajek R.** Perspective combo regimens in near future: focus on proteasome inhibitors and IMiDs in multiple myeloma. Katedra i Klinika Hematologii Collegium Medicum UJ, Krakow, Poland, February 2014.

1/2014 Rakousko

- **Hajek R.** MGUS, SMM and MM: Risk factors and clinical implications. **29. TANNHEIMER SYMPOSIUM HĀMATOLOGIE IM FOKUS – MULTIPLES MYELOM**, Tannheim, Austria, January 2014.

1/2014 Polsko

- **Hajek R.** Current Perspectives of SMM Treatment. **4. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2014.

1 – 12/ 201312/2013 USA

- **Hájek R.** - předsednictví sekce Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients, **55th ASH Annual Meeting**, New Orleans, USA, December 2013.

11/2013 Itálie

- **Hájek R.** Markers predicting transitiv of MGUS into myeloma, **The educational Course: "Multiple Myeloma and Related Malignancies, 2nd Edition"**, Bari, Italy, November 2013.

10/2013 Irsko

- **Hájek R.** MLN 9708, **ESH International Conference on Multiple Myeloma**, Dublin, Ireland, October 2013.

4/2013 Japonsko

- Gay F., **Hajek R.**, Di Raimondo F., et al. Cyclophosphamide-Lenalidomide-Dexamethasone vs Autologous Transplant in Newly Diagnosed Myeloma: a Phase 3 Trial., **14th International Myeloma Workshop, IMW 2013**, Kyoto, April 2013.
- Delforge M., Dimopoulos M., Adam Z., **Hajek R.**, Yu Z., Herbein L., Jacques C., Palumbo A. Long-term Safety of Continuous Lenalidomide Therapy in Newly Diagnosed Multiple Myeloma Patients: MM-015 Update. **14th International Myeloma Workshop, IMW 2013**, Kyoto, April 2013.

2/2013 Německo

- Hájek R. New data with new agents, **The Multiple Myeloma Debates 2013: Recent Advances in Multiple Myeloma Educational Updates from ASH 2012**, Berlin, Germany, February 2013.

1/2013 Polsko

- **Hájek R.** Clonaltide and its implications for future treatment strategies, **3. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT**, Warsaw, Poland, January 2013.